Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review.

Anaphylaxis Hereditary alpha Tryptasemia MCAS Mast cells Mastocytosis Tryptase Vienna consensus criteria

Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
11 2021
Historique:
received: 08 05 2021
revised: 05 06 2021
accepted: 11 06 2021
pubmed: 25 6 2021
medline: 15 12 2021
entrez: 24 6 2021
Statut: ppublish

Résumé

In recent years, knowledge about mechanisms underlying mast cell activation (MCA) and accumulation in various pathologic conditions increased substantially. In addition, criteria and a classification of MCA syndromes (MCASs) have been set forth. MCAS is defined by typical clinical symptoms, a substantial increase in serum tryptase level during an attack over the patient's baseline tryptase, and a response of the symptoms to drugs targeting mast cells, mediator production, and/or mediator effects. Alternative diagnostic criteria of MCAS have also been suggested, but these alternative criteria often lack specificity and validation. In this report, we critically review the contemporary literature relating to MCAS and compare the specificity, sensitivity, and strength of MCAS-related parameters within proposals to diagnose and classify MCAS and its variants. Furthermore, we highlight the need to apply specific consensus criteria in the evaluation and classification of MCAS in individual patients. This is an urgent and important medical necessity because as an increasing number of patients are being given a misdiagnosis of MCAS based on nonspecific criteria, which contributes to confusion and frustration by patients and caregivers and sometimes may delay recognition and treatment of correct medical conditions that often turn out to be unrelated to MCA.

Identifiants

pubmed: 34166845
pii: S2213-2198(21)00676-0
doi: 10.1016/j.jaip.2021.06.011
pii:
doi:

Substances chimiques

Tryptases EC 3.4.21.59

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3918-3928

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Theo Gülen (T)

Department of Respiratory Medicine and Allergy, Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden. Electronic address: theo.gulen@sll.se.

Cem Akin (C)

Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich.

Patrizia Bonadonna (P)

Allergy Unit, Verona University Hospital, Verona, Italy.

Frank Siebenhaar (F)

Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Sigurd Broesby-Olsen (S)

Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.

Knut Brockow (K)

Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Germany.

Marek Niedoszytko (M)

Department of Allergology, Medical University of Gdansk, Gdansk, Poland.

Boguslaw Nedoszytko (B)

Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland; Invicta Fertility and Reproductive Center, Molecular Laboratory, Sopot, Poland.

Hanneke N G Oude Elberink (HNG)

Department of Allergology, GRIAC Research Institute, University of Groningen, University Medical Center of Groningen, Groningen, The Netherlands.

Joseph H Butterfield (JH)

Division of Allergic Diseases, Mayo Clinic, Rochester, Minn.

Wolfgang R Sperr (WR)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Ivan Alvarez-Twose (I)

Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo, Spain.

Hans-Peter Horny (HP)

Institute of Pathology, Ludwig-Maximilian University, Munich, Germany.

Karl Sotlar (K)

Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria.

Juliana Schwaab (J)

Allergy Unit, Verona University Hospital, Verona, Italy.

Mohamad Jawhar (M)

Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.

Roberta Zanotti (R)

Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.

Gunnar Nilsson (G)

Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.

Jonathan J Lyons (JJ)

Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Melody C Carter (MC)

Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Tracy I George (TI)

Department of Pathology, University of Utah, Salt Lake City, Utah.

Olivier Hermine (O)

Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre National de Référence des Mastocytoses, Paris, France.

Jason Gotlib (J)

Stanford Cancer Institute/Stanford University School of Medicine, Stanford, Calif.

Alberto Orfao (A)

Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC/USAL), IBSAL, CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Spain.

Massimo Triggiani (M)

Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.

Andreas Reiter (A)

Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.

Karin Hartmann (K)

Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.

Mariana Castells (M)

Brigham and Women's Hospital, Mastocytosis Center, Harvard Medical School, Boston, Mass.

Michel Arock (M)

Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), Paris, France.

Lawrence B Schwartz (LB)

Department of Internal Medicine, Division of Rheumatology, Allergy, and Immunology, Virginia Commonwealth University, Richmond, Va.

Dean D Metcalfe (DD)

Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Peter Valent (P)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH